Riverside, Calif. – Meet MYC, the shapeless protein responsible for making the majority of human cancer cases worse. UC Riverside researchers have found a way to rein it in, offering hope for a new era of treatments. In healthy cells, MYC helps guide the process of transcription, in which genetic...
research News
Lisboa, Portugal – Using zebrafish “Avatars”, an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD student at the lab now working at the Universidad de las Américas in Quito, Ecuador –...
New York, NY – A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer treatments, according to a new study from researchers at Weill Cornell Medicine. In the study, published Dec. 26 in Cell Stem Cell, the scientists...
GROSSE POINTE, Mich. — SciTech Development, a clinical-stage pharmaceutical company with a novel and patented drug delivery platform, today announced that the company has dosed the first patient in its Phase 1 clinical trial with lead cancer drug candidate, ST-001 nanoFenretinide. “There have been relatively few new cancer breakthroughs for...
HANGZHOU, China and SAN FRANCISCO, CA — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive topline results from a Phase 3 clinical trial of ecnoglutide (XW003) in Chinese adults with type 2 diabetes mellitus (T2DM). Ecnoglutide...
Granada, Spain – A study carried out by the MP20-Biomarkers of Metabolic and Bone Diseases research group at the Biohealth Research Institute in Granada (ibs.GRANADA), led by UGR Professor Manuel Muñoz Torres, has provided significant insights into the role of sclerostin in protecting against atherosclerosis in patients with type 2...
JUPITER, FL. – Current tests to identify specific strains of infectious prions, which cause a range of transmissible diseases (such as mad cow) in animals and humans, can take anywhere from six months to a year to yield results – a time-lag that may put human populations at risk. Now,...
LA JOLLA, CA—Hitting targets embedded within the cell membrane has long been difficult for drug developers due to the membrane’s challenging biochemical properties. Now, Scripps Research chemists have demonstrated new custom-designed proteins that can efficiently reach these “intramembrane” targets. In their study, published in Nature Chemical Biology, the researchers used...
LA JOLLA, CA — Hormone-driven cancers, like those of the breast and prostate, often rely on a tricky-to-target protein called Forkhead box protein 1 (FOXA1). FOXA1 mutations can enable these types of cancers to grow and proliferate. Today, FOXA1 is notoriously difficult to block with drugs—but that may soon change....
DENVER, CO — SeaStar Medical Holding Corporation, a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces enrollment of 12 subjects in the NEUTRALIZE-AKI pivotal clinical trial evaluating the safety and efficacy of its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy...